Dosing of First Patient in a Trial for LSALT Peptide is Sending Shares HIgher
11 Novembre 2024 - 7:46PM
AllPennyStocks.com
This late-stage clinical trial company focuses on preventing
inflammation and acute organ injury. It is developing a platform of
new drugs to prevent inflammation in the kidneys, liver and
lungs...
To read the full story on AllPennyStocks.com, click
here.
Grafico Azioni Arch Biopartners (TSXV:ARCH)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Arch Biopartners (TSXV:ARCH)
Storico
Da Gen 2024 a Gen 2025